Cancer

May 26, 2015, by NCI Staff Flexible sigmoidoscopy (pictured above) examines the lower portion of the colon, where many polyps and cancers are found. Screening rates for breast, colorectal, and cervical cancer are lagging behind target rates set by the Healthy People 2020 program, according to a new study by researchers from the Centers for
0 Comments
May 15, 2015, by Peter F. Garrett, Director, NCI OCPL Millions of people depend on the National Cancer Institute (NCI), the nation’s leading cancer research institution, for trusted cancer information. There have been many changes in how people get information about cancer, and NCI has changed along with them. Today, we are launching a new, dynamic,
0 Comments
April 27, 2015, by NCI Staff Staining slide showing range of PD-L1 expression in non-small cell lung carcinoma. Images courtesy of Dako North American, Inc. Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab
0 Comments
April 23, 2015, by NCI Staff A new NCI study forecasts important trends in breast cancer case types and molecular makeup.  Several studies have already forecasted that the incidence of U.S. breast cancer cases is expected to increase in the coming decades, largely the result of an aging population. Now, a new study presented by
0 Comments
April 22, 2015, by NCI Staff Persistent infections with high-risk HPV types can cause cancer at several different anatomic sites. Persistent HPV infections, especially HPV-16, for example, are a key risk factor for oropharyngeal cancer, which involves the tonsils or the base of the tongue. Vaccination against high-risk types of human papillomavirus (HPV) protected young
0 Comments
April 21, 2015, by Douglas Lowy, M.D. Douglas R. Lowy, M.D., during the Plenary Session: Precision Medicine Comes to Cancer Prevention and Screening at the American Association for Cancer Research Annual Meeting, April 20, 2015. © AACR/Phil McCarten 2015 Yesterday, at the annual meeting of the American Association for Cancer Research (AACR), I had my
0 Comments
April 17, 2015, by NCI Staff Cancer surveillance science involves understanding and reporting the most relevant and available patient information to provide a complete picture of a patient’s cancer. On April 15, NCI’s Surveillance, Epidemiology, and End Results (SEER) Program published the latest data on U.S. cancer incidence. Since the early 1970s, SEER has been
0 Comments
April 15, 2015, by NCI Staff Imaged using a technique known as spectral karyotyping, these chromosomes, prepared from a glioblastoma sample, reveal an enormous degree of chromosomal instability—a hallmark of cancer. Microscopes have come a long way since 17th-century English scientist Robert Hooke peered through his leather- and gold-tooled instrument and discovered the cell.  Today’s
0 Comments
April 14, 2015, by Robert Croyle, Ph.D. Robert Croyle, Ph.D., Director, Division of Cancer Control and Population Sciences Ongoing concerns regarding the cost and quality of cancer care have led many organizations to focus greater attention on the non-biological factors that contribute to variation in outcomes. Health care delivery systems are struggling to understand how best
0 Comments
April 9, 2015, by NCI Staff Frank McCormick, Ph.D.RAS National Program AdvisorProfessor Emeritus, UCSF Helen Diller Family Comprehensive Cancer Center Frank McCormick, Ph.D., leads the NCI-sponsored RAS Initiative at the Frederick National Laboratories for Cancer Research (FNLCR). In this interview, Dr. McCormick talks about the history, the challenges, and the future of RAS research. What
0 Comments
April 9, 2015, by NCI Staff Often described as heart-shaped, the RAS protein plays an important role in cell division and growth. Every year, more than one million people worldwide die from cancers driven by mutations in a gene called RAS. Despite the success in developing cancer therapies that target many genetic abnormalities that drive
0 Comments
April 1, 2015, by Douglas Lowy, M.D. Douglas R. Lowy, M.D.Deputy Director, National Cancer Institute As many of you are aware, I have become Acting Director of the National Cancer Institute (NCI). I have known many of you for years, and look forward to working together in my new role at the Institute. I would
0 Comments
March 31, 2015, by Malcolm A. Smith, M.D., Ph.D. Malcolm A. Smith, M.D., Ph.D.Associate Branch Chief, PediatricsNCI Cancer Therapy Evaluation Program Challenges to childhood cancer researchers moving forward are to go beyond 90 percent survival for diseases like acute lymphoblastic leukemia (ALL) and to find cures for those cancers for which we still have no
0 Comments
March 30, 2015, by NCI Staff Today, NCI, the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), and the North American Association of Central Cancer Registries (NAACCR) issued the Annual Report to the Nation. This report is one of several regularly released reports that provide information on important cancer trends in
0 Comments
March 27, 2015, by NCI Staff Neuroblastoma may be found in the adrenal glands and paraspinal nerve tissue from the neck to the pelvis. The Food and Drug Administration (FDA) has approved dinutuximab (Unituxin™) as part of first-line therapy for children with high-risk neuroblastoma—the first approval of a therapy specifically for patients with the high-risk
0 Comments
March 24, 2015, by NCI Staff Specific DNA changes in a tumor may help determine which patients are most likely to respond to treatment with PD-1 inhibitors, according to findings from a new study by researchers at Memorial Sloan Kettering Cancer Center. The FDA has approved two PD-1 inhibitors: nivolumab (Opvido) and pembrolizumab (Keytruda). Both
0 Comments
March 24, 2015, by NCI Staff On March 4, the U.S. Food and Drug Administration approved nivolumab (Opdivo) to treat patients with advanced non-small cell lung cancer (NSCLC) that has progressed during or after treatment with platinum-based chemotherapy. Nivolumab, which was initially approved for the treatment of metastatic melanoma, is the first immunotherapy drug to
0 Comments
March 24, 2015, by NCI Staff As part of its Exceptional Responders Initiative, NCI continues to reach out to the oncology community. The initiative is collecting cases in which patients with any cancer had dramatic and long-lasting responses to standard and experimental treatments that were not seen in similar patients who received the same treatment.
0 Comments
March 9, 2015, by NCI Staff At the recent annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, several NCI researchers and NCI-funded investigators presented new findings on HIV-related cancers. While the conference was fairly wide-ranging, some of the more interesting and clinically applicable findings evolved around a better understanding of AIDS-related malignancies, explained
0 Comments